Ventavis® Registry Protocol

Conditions

Pulmonary Arterial Hypertension

What is the purpose of this trial?

The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months. Patients diagnosed with WHO Group I PAH who are on a stable regimen of commercial Ventavis® will be followed for a maximum of 2 years from the time of enrollment. Data will be collected via patient interview and review of the medical record. Quarterly data collection will include capture of medications and Ventavis® adherence data.



Participation Guidelines

Age:
19 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Actelion
Dates:
March 2009
Last Updated:
July 16, 2013
Study HIC#:
1003006408

Clinicaltrials.gov ID: NCT00902603